Alzheimer disease and Parkinson disease do not appear to share common genetic risk

August 5, 2013

A study by Valentina Moskvina, Ph.D., of the Cardiff University School of Medicine, Wales, United Kingdom, and colleagues, examined the genetic overlap between Parkinson disease (PD) and Alzheimer disease (AD).

Data sets from the United Kingdom, Germany, France and the United States were used to perform a combined genome-wide association analysis (GWA). The GWA study of AD included 3,177 patients with AD and 7,277 control patients, and the GWA analysis for PD included 5,333 patients with PD and 12,298 control patients. The gene-based analyses resulted in no significant evidence that supported the presence of loci (location of gene) that were associated with increased risk for both PD and AD, according to the study results.

"Our findings therefore imply that loci that increase the risk of both PD and AD are not widespread and that the pathological overlap could instead be 'downstream' of the primary that increase the risk of each disease," the study concludes.

Explore further: New findings, imaging may aid diagnosis of concomitant AD in patients with Parkinson's disease dementia

More information: JAMA Neurol. Published online August 5, 2013. doi:10.1001/.jamaneurol.2013.448

Related Stories

Five CSF markers differentiate dementia, parkinsonism

August 28, 2012

(HealthDay)—Levels of five different cerebrospinal fluid (CSF) biomarkers are able to improve differentiation between common dementia and parkinsonian disorders, according to a study published online Aug. 27 in the Archives ...

Diabetes drug tested in Parkinson's disease patients

May 20, 2013

Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the ...

Recommended for you

Major complication of Parkinson's therapy explained

September 10, 2015

Researchers have discovered why long-term use of L-DOPA (levodopa), the most effective treatment for Parkinson's disease, commonly leads to a movement problem called dyskinesia, a side effect that can be as debilitating as ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.